PharmaFocus: Supportive Care in Oncology

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Supportive care in oncology is a broad term that is composed of indications that are either a symptom of a patient’s cancer or a side effect of cancer treatment. This report focuses on six prominent cancer supportive care indications: chemotherapy-induced nausea and vomiting (CINV), cancer cachexia, oral mucositis, bone metastases, chemotherapy-induced neutropenia (CIN), and chemotherapy-induced anemia (CIA).
There is a consensus among KOLs across the 7MM that supportive oncology had not been given much priority by physicians and institutions in the past. However, there is also a consensus that this situation has been improving in recent years, with increasing recognition of the importance of supportive care.
A growing library of evidence indicates that supportive care: increases likelihood of completing treatment, without the need for dose reductions or treatment pauses; can reduce costs for healthcare institutions; and can improve quality of life for patients—all of which will become increasingly important as patients continue to live longer and cancer progresses to become more like a chronic disease. Despite the trends in oncology towards targeted therapies, KOLs agree that chemotherapy will remain the backbone of cancer treatment for the next five to 10 years. Thus, as the incidence of cancer rises over the next 10 years, so will the cases of chemotherapy-related conditions, in addition to a rise in general oncology-related conditions.


Highlight KOL views on the past, present, and future trends in supportive care in oncology in their countries

Provide cancer and cancer supportive care epidemiological insight

Provide an overview of the market landscape and available therapies

Provide an overview of all late-stage (Phase II and III) candidates and evaluate the prominent pipeline agents that are closest to market entry

Identify the unmet needs and opportunities in each indication

Highlight R&D strategies used by developers in this field, alongside clinical trial design considerations and challenges

Provide detailed key opinion leader insight throughout each indication and aspect of this report

Reasons to Buy

The report will enable you to:

Develop business strategies by understanding the trends shaping and driving the global supportive care in oncology market

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global supportive care market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Acacia Pharma
Aeterna Zentaris
Aphios Corporation
BeyondSpring Pharmaceuticals
Cellerant Therapeutics
Coherus Biosciences
Eli Lilly
Enzychem Lifesciences Corp
Galera Therapeutics
Gedeon Richter
Generon (Shanghai) Corp Ltd
Hanmi Pharmaceuticals
Heron Therapeutics
Innovation Pharmaceuticals
Insys Therapeutics
Johnson & Johnson
Merck & Co.
Monopar Therapeutics
Myelo Therapeutics GmbH
Paradigm BioPharma
R-Pharm US LLC
SBI Pharmaceuticals
Soligenix Inc.
Spectrum Pharmaceuticals
Spherium Biomed
Taiho Pharmaceutical
Tanvex biopharma Inc
USV Pvt Ltd

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Traditionally Overlooked Field, but Recognition of Supportive Oncology is Growing Across the 7MM, and will Continue to do so in the Next Five to Ten Years.

2.2 Marketed Landscape Varies Significantly – Blockbuster Drugs in CIN, CIA, and Bone Metastases, but Nothing Available for Cancer Cachexia

2.3 CIN and Oral Mucositis Possess the Largest Late Stage (Phase II and III) Pipelines

2.4 Unmet Needs Remain in Each Indication, Primarily in Cancer Cachexia and Oral Mucositis, Given the Lack of Effective Therapies

2.5 R&D and Clinical Trial Design in Supportive Oncology Presents Unique Challenges

2.6 What Do Physicians Think?

3 Introduction

3.1 Objectives

3.2 Related Reports

4 Supportive Care in Oncology Global Landscape: KOL Views

4.1 Overview

4.2 US Supportive Care Landscape

4.2.1 Current Status of Supportive Care in Oncology

4.2.2 Physician and Patient Attitudes Towards Supportive Care in Oncology

4.2.3 Future Trends

4.3 UK Supportive Care Landscape

4.3.1 Current Status of Supportive Oncology and Physician/Patient Attitudes towards Supportive Oncology

4.3.2 Future Trends

4.4 Germany Supportive Care Landscape

4.4.1 Current Status of Supportive Oncology and Physician/Patient Attitudes towards Supportive Oncology

4.4.2 Future Trends

4.5 Spain Supportive Care Landscape

4.6 Japan Supportive Care Landscape

4.6.1 Who Provides Supportive Care in Japan

4.6.2 Current State of Supportive Oncology in Japan

4.6.3 Future Trends

4.7 Guidelines Followed by KOLs

4.7.1 Chemotherapy Induced Nausea and Vomiting

4.7.2 Chemotherapy-Induced Neutropenia

5 Epidemiology

5.1 Cancer Background, Global and Historic Trends

5.2 Methodology and Sources

5.2.1 Assumptions and Methods

5.3 Epidemiology for Supportive Care in Oncology (2016–2026)

5.3.1 Diagnosed Incident Cases of All Cancer

5.3.2 Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment

5.3.3 Diagnosed Incident Cases of Chemotherapy-Induced Conditions

5.3.4 Diagnosed Incident Cases of Prostate Cancer

5.3.5 Diagnosed Incident Cases of Prostate Cancer That Develop Bone Metastasis

5.3.6 Diagnosed Incident Cases of Breast Cancer

5.3.7 Diagnosed Incident Cases of Breast Cancer That Develop Bone Metastasis

5.3.8 Diagnosed Incident Cases of Lung Cancer

5.3.9 Diagnosed Incident Cases of Lung Cancer that Develop Bone Metastasis

5.3.10 Five-Year Diagnosed Prevalent Cases of All Cancer

5.4 Discussion, Limitations and Strengths of Analysis

6 Marketed Products

6.1 Chemotherapy-Induced Nausea and Vomiting

6.1.1 Emend and Emend for Injection

6.1.2 Varubi and Varubi IV

6.1.3 Aloxi

6.1.4 Sustol

6.1.5 Akynzeo

6.1.6 Syndros and Marinol

6.1.7 Olanzapine – Off-Label Use

6.2 Cancer Cachexia

6.3 Oral Mucositis

6.3.1 Kepivance

6.3.2 Mucosta (Off-Label) and Gels for Oral Mucositis

6.4 Bone Metastases

6.4.1 Xgeva

6.4.2 Xofigo

6.4.3 Zometa and Aredia

6.5 Chemotherapy-Induced Neutropenia

6.5.1 Neupogen

6.5.2 Filgrastim Biosimilars

6.5.3 Granix and Granocyte

6.5.4 Neulasta

6.5.5 Lonquex and Leukine

6.6 Chemotherapy Induced Anemia

6.6.1 Procrit/Eprex/Epogen

6.6.2 Epoetin Alfa Biosimilars, NeoRecormon, and Eporatio / Biopoin

6.6.3 Aranesp

7 Pipeline Assessment

7.1 Chemotherapy-Induced Nausea and Vomiting

7.1.1 CINV Phase II and III Pipeline

7.1.2 APD403 (Amisulpride) – Acacia Pharma

7.1.3 Cinvanti (Aprepitant/HTX-019) – Heron Therapeutics

7.2 Cancer Cachexia

7.2.1 Cancer Cachexia Phase II and III Pipeline Overview

7.2.2 Adlumiz (Anamorelin) – Helsinn

7.2.3 Xilonix (MABp1) – XBiotech

7.3 Oral Mucositis

7.3.1 Oral Mucositis Phase II and III Pipeline Overview

7.3.2 SGX942 (Dusquetide) – Soligenix Inc.

7.3.3 Validive (Clonidine Lauriad) – Onxeo/Monopar Therapeutics

7.4 Bone Metastases

7.4.1 Bone Metastases Phase II and III Pipeline Overview

7.4.2 Tanezumab – Pfizer and Eli Lilly

7.5 Chemotherapy-Induced Neutropenia

7.5.1 CIN Phase II and III Pipeline Overview

7.5.2 Rolontis (eflapegrastim/SPI-2012) – Spectrum Pharmaceuticals and Hanmi Pharmaceuticals

7.5.3 Plinabulin (NPI-2358) – BeyondSpring Pharmaceuticals

7.6 Chemotherapy-Induced Anemia

7.6.1 CIA Phase II and III Pipeline Overview

7.6.2 SPP-003 (5-Aminolevulinic Acid Hydrochloride and Sodium Ferrous Citrate) – SBI Pharmaceuticals

8 Unmet Needs and Opportunities

8.1 Chemotherapy-Induced Nausea and Vomiting

8.1.1 Therapies with More Effective Control of Nausea

8.1.2 Novel Mechanisms of Action and Differentiation from Currently Available Therapies

8.1.3 CINV Treatment/Regimens for Oral Anti-Cancer Drugs

8.1.4 Education of Stakeholders on Available Treatment Options and Proper Utilization

8.1.5 Other Unmet Needs

8.2 Cancer Cachexia

8.2.1 Huge Unmet Need for Treatments

8.2.2 Need for Improved Diagnosis and Identification of Cachexia in Obese Patients

8.2.3 Lack of Research, and Cachexia Not Given Priority in Cancer Care

8.3 Oral Mucositis

8.3.1 Need for Effective Treatments

8.3.2 Improved Forms of Administration

8.4 Bone Metastases

8.4.1 New Targets and Novel Mechanisms of Action

8.4.2 Improvements in Quality of Life and in Pain

8.4.3 Therapies with Oral Administration

8.4.4 Further Investigation of Corticosteroids for Painful Bone Metastases

8.5 Chemotherapy-Induced Neutropenia

8.5.1 New Treatments to Update Regimens from the Decades-Old Therapies Currently Available

8.5.2 New Forms of Administration, Fewer Side Effects, and Biomarkers

8.6 Chemotherapy-Induced Anemia

8.6.1 Therapies with a Better Side Effect Profile and Faster Demonstration of Effectiveness than ESAs

8.6.2 Further Investigation of IV Iron in CIA, and Subsequent Update to Treatment Guidelines

9 R&D Strategies and Clinical Trial Design

9.1 Overview of Clinical Development in Supportive Oncology

9.2 Chemotherapy-Induced Nausea and Vomiting

9.2.1 R&D Strategies

9.2.2 Clinical Trial Design Considerations

9.3 Cancer Cachexia

9.3.1 R&D Strategies

9.3.2 Clinical Trial Design Considerations

9.4 Oral Mucositis

9.4.1 R&D Strategies

9.4.2 Clinical Trial Considerations

9.5 Bone Metastasis

9.5.1 R&D Strategies and Clinical Trial Considerations

9.6 Chemotherapy-Induced Neutropenia

9.6.1 R&D Strategies

9.6.2 Clinical Trial Design Considerations

9.7 Chemotherapy-Induced Anemia

9.7.1 R&D Strategies and Clinical Trial Design Considerations

10 Appendix

10.1 Bibliography

10.2 Abbreviations

10.3 Primary Research – KOLs Interviewed for This Report

10.4 About the Authors

10.4.1 Analyst

10.4.2 Therapy Area Director

10.4.3 Epidemiologists

10.4.4 Reviewers

10.4.5 Global Director of Therapy Analysis and Epidemiology

10.4.6 Global Head and EVP of Healthcare Operations and Strategy

10.5 About GlobalData

10.6 Contact Us

10.7 Disclaimer

Frequently asked questions

PharmaFocus: Supportive Care in Oncology thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

PharmaFocus: Supportive Care in Oncology was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Oncology reports
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PharmaFocus: Supportive Care in Oncology in real time.

  • Access a live PharmaFocus: Supportive Care in Oncology dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.